Polyrizon Ltd. (PLRZ)
| Market Cap | 17.57M +750.8% |
| Revenue (ttm) | n/a |
| Net Income | -3.34M |
| EPS | -4.90 |
| Shares Out | 1.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,079 |
| Open | 11.90 |
| Previous Close | 10.75 |
| Day's Range | 10.52 - 11.90 |
| 52-Week Range | 2.88 - 2,235.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 17, 2026 |
About PLRZ
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israe... [Read more]
Financial Performance
Financial StatementsNews
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announce...
Polyrizon Provides 2025 and Recent Highlights
Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significan...
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions,...
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutio...
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutio...
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solution...
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding pro...
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted E...
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
T he Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted ...
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical developme...
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Company Remains Fully Committed to Advancing Its Core Intranasal Medical Pipeline, alongside examining new opportunities including in fields of aviation, AI and defense
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon...
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protect...
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a mutated strain of influenza A is driving most cases, sparking concerns about a po...
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd.
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company ...
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
Ra'anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today anno...
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
Ra'anana, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today anno...
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
Ra'anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshapi...
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra'anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ...
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
Ra'anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Captur...
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
In-Vitro Data Confirms Strong Protection Against H1N1 Influenza via Physical Barrier Mechanism Ra'anana, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Co...
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Ra'anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Captur...